IL18 and neoplasm: In addition, IL-18 CAR T-cell treatment of large pancreatic and lung tumors showed changes in the immune cell landscape; significant increases in macrophages (CD 206 M1) and NKs (NKG2D+) were observed Apart from this, a decrease in Tregs such as M2 macrophage-suppressive CD 103 + DCs, indicates the ability of “IL-18 TRUCKs” to sensitize large tumor lesions for effective immune destruction (Hurton et al., 2016).